OBR Summer News Flash
Most Popular News Stories on OBR Daily
The ten most read articles from OBR Daily in the past month, updated continually:
(StreetInsider) Sept 7, 2017 - Pivotal trial of indoximod in advanced melanoma to include both PD-1 inhibitors, KEYTRUDA (pembrolizumab) and OPDIVO® (nivolumab).
(StreetInsider) Aug 30, 2017 - Updated Phase 1 and new Phase 2 data from the ECHO-202 trial to be highlighted as an oral presentation at ESMO 2017 Congress.
(StreetInsider) Sept 15, 2017 - Myriad Genetics, Inc. today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors (NSGC) in Columbus, OH.
(Roche) Sep 6, 2017 - Roche today announced results from the global phase III ALUR study showing that Alecensa® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), who had progressed following treatment with platinum-based chemotherapy and crizotinib (hazard ratio [HR]=0.15, 95% CI: 0.08-0.29, p<0.001).
(Xconomy New York) Sept 5, 2017 - The FDA has forced Cellectis to shut down two Phase 1 trials it has been running to test an “off the shelf” type of cell therapy—a stinging setback to the France- and New York-based company’s aspirations to leapfrog other developers of CAR-T, a type of cancer immunotherapy that the FDA just approved for the first time last week.
(STAT/The Pharmalot View) Sept 4, 2017 - A first-of-its-kind cancer treatment is generating unbridled excitement — but also underscoring intense concerns over pricing and value.
(Endpoints News) Sept 1, 2017 - Back in late 2014, MacroGenics CEO Scott Koenig touted the potential of his bispecific CD19/CD3 drug for B-cell malignancies, claiming MGD011 (duvortuxizumab) looked like it could beat the CAR-T drugs that were beginning to gather rapt attention.
(StreetInsider) Sept 7, 2017 - Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION™ program.
(STAT/In the Lab) Aug 27, 2017 - Researchers have found that the anti-inflammatory drug canakinumab from Novartis had a surprising (and welcome) side effect in a study on cardiovascular dissese: It also sharply cut the rates of lung cancer.
(STAT) Aug 30, 2017 - The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.